h-R3: Treatment of Head and Neck Cancer Treatment of Epithelial Tumors Anti-EGFR MAb

Drugs of the Future

Volumn 28, Issue 9, 2003, Pages 847-853

  Crombet Ramos, T ^a   Parada, A Casacó ^a   Iznaga Escobar, N ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY H R3; NIMOTUZUMAB; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ACNE; ADVANCED CANCER; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; ASTHENIA; BLEEDING; CANCER RADIOTHERAPY; CELL CYCLE; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DISEASE COURSE; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSPHAGIA; ENZYME INHIBITION; EPITHELIUM TUMOR; EPITOPE MAPPING; FEMALE; FEVER; FLUSHING; FOLLICULITIS; GENE OVEREXPRESSION; GENETIC ENGINEERING; HEAD AND NECK CANCER; HEADACHE; HEMATOMA; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYPERTENSION; HYPOTENSION; INFLAMMATION; INHIBITION KINETICS; MITOSIS RATE; MOUSE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN LOCALIZATION; RAT; REMISSION; SIDE EFFECT; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; TOXICITY TESTING; TREMOR; VOMITING; XEROSTOMIA;

EID: 0345732698     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.09.755207     Document Type: Article

References (36)

1. Mateo, C., Moreno, E., Amour, K., Lombardero, J., Harris, W., Perez, R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: Recovery of antagonistic activity. Immunotechnology 1997, 3: 71-81.
2. Fernandez, A., Spitzer, E., Perez, R., Boehmer, F.D., Eckert, K., Zschiesche, W., Grosse, R. A new monoclonal antibody for detection of the EGF-R in Western Blot and paraffin embedded tissue sections. J Cell Biochem 1992, 49: 157-65.
3. Shawver, L.K., Slamon, D., Ullrich, A. Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1: 117-23.
4. Schmandt, R.E., Broaddus, R., Lu, K.H., Shvartsman, H., Thornton, A., Malpica, A., Sun, C., Bodurka, D.C., Gershenson, D.M. Expression of c-ABL, c-KIT and platelet-derived growth factor receptor-β in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003, 98: 758-64.
5. Sattler, M., Scheijen, B., Weisberg, E., Griffin, J.D. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv Exp Med Biol 2003, 532: 121-40.
6. Xu, Y.H., Ishii, S., Clark, A.J., Sullivan, M., Wilson, R.K., Ma, D.P., Roe, B.A., Merlino, G.T., Pastan, I. Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells. Nature 1984, 309: 806-10.
7. Ullrich, A., Coussens, L., Hayflick, J.S. et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984, 309: 418-25.
8. Merlino, G.T., Xu, Y.H., Ishii, S., Clark, A.J., Semba, K., Toyoshima, K., Yamamoto, T., Pastan, I. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science 1984 224: 417-9.
9. Arteaga, C. Targeting HER1/EGFR: A molecular approach to cancer therapy. Semin Oncol 2003 30(3, Suppl. 7): 3-14.
10. Ciardiello, F., Tortora, G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003, 39: 1348-54.
11. Bunn, P.A. Jr., Franklin, W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002, 29(5, Suppl. 14): 38-44.
12. Ke, L.D., Adler-Storthz, K., Clayman, G.L., Yung, A.W., Chen, Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck 1998, 20: 320-7.
13. Nahta, R., Hortobagyi, G.N., Esteva, F.J. Growth factor receptors in breast cancer: Potential for therapeutic intervention. Oncologist 2003, 8: 5-17.
14. Liu, T.F., Tatter, S.B., Willingham, M.C., Yang, M., Hu, J.J., Frankel, A.E. Growth factor receptor expression varies among high-grade gliomas and normal brain: Epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ther 2003, 2: 783-7.
15. Bellmunt, J., Hussain, M., Dinney, C.P. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003, 46(Suppl.): 85-104.
16. Daveau, M., Scotte, M., Francois, A., Coulouarn, C., Ros, G., Tallet, Y., Hiron, M., Hellot, M.F., Salier, J.P. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 2003, 36: 130-41.
17. Koyama, S., Maruyama, T., Adachi, S. Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: A two-color flow-cytometric analysis. J Cancer Res Clin Oncol 1999, 125: 47-54.
18. Kopp, R., Rothbauer, E., Ruge, M., Arnholdt, H., Spranger, J., Muders, M., Pfeiffer, D.G., Schildberg, F.W., Pfeiffer, A. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: Evidence for new therapeutic options. Recent Results Cancer Res 2003, 162: 115-32.
19. Yoshimoto, T., Takahashi, Y., Kinoshita, T., Sakashita, T., Inoue, H., Tanabe, T. Growth stimulation and epidermal growth factor receptor induction in cyclooxygenase-overexpressing human colon carcinoma cells. Adv Exp Med Biol 2002, 507: 403-7.
20. Kim, E.S., Khuri, F.R., Herbst, R.S. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001, 3: 506-13.
21. Liang, K., Ang, K.K., Milas, L., Hunter, N., Fan, Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003, 57: 246-54.
22. Baselga, J., Albanell, J. Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North Am 2002, 16: 1041-63.
23. Grunwald, V., Hidalgo, M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003, 95: 851-67.
24. Gonzalez, G., Crombet, T., Torres, F. et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003, 14: 461-6.
25. Thomas, S.M., Zeng, Q., Dyer, K.F., Suscovich, T.J., Kanter, P.M., Whalen, J.D., Watkins, S.F., Grandis, J.R. Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy. Cancer Gene Ther 2003, 10: 518-28.
26. 99mTc-Labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy. J Nucl Med 1999, 40: 768-75.
27. Crombet, T., Torres, O., Neninger, E., Catala, M., Rodriguez, N., Ramos, M., Fernandez, E., Iznaga, N., Perez, R., Lage, A. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother Radiopharm 2001, 16: 93-102.
28. Crombet, T., Torres, O., Rodriguez, V. et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study. Hybridoma 2001, 20: 131-6.
29. Morales, A.A., Duconge, J., Alvarez-Ruiz, D., Becquer-Viart, M.L., Nunez-Gandolff, G., Fernandez, E., Caballero-Torres, I., Iznaga-Escobar, N. Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies. Nucl Med Biol 2000 27: 199-206.
30. Sgouros, G., Yang, W.H., Enmon, R. Spheroids of prostate tumor cell lines. Methods Mol Med 2003, 81: 79-88.
31. Crombet-Ramos, T., Rak, J., Perez, R., Viloria-Petit, A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002 101: 567-75.
32. 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats. Nucl Med Biol 1998, 25: 17-23.
33. Crombet, T., Torres, L., Neninger, E. et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003, 26: 139-48.
34. Crombet, T., Torres, L., Solano, M. et al. Pharmacological and clinical evaluation of the humanized anti-EGF-R monoclonal antibody, h-R3, in patients with advanced epithelial carcinomas. Proc Am Soc Clin Oncol 2001 20(Part 1): Abst 1012.
35. Crombet, T., Osorio, M., Cruz, T., Figueredo, R., Koropatnick, J., Reginfo, E., Torres, O., Pérez, R., Lage, A. Use of the anti-EGFR antibody h-R3 in combination with radiotherapy in the treatment of advanced head and neck cancer. Proc Am Soc Clin Oncol 2002; 21(Part 1): Abst 53.
36. Winquist, E., Nabid, A., Sicheri, D., Ganguly, P., Venkatesan, V., Schneider, K., McKinnon, J., Laurie, S. A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). Proc Am Soc Clin Oncol 2002, 21(Part 1): Abst 926.